Literature DB >> 7273010

Chemotherapy for colorectal cancer with a combination of PALA and 5-FU.

A Y Bedikian, J R Stroehlein, D A Karlin, R W Bennetts, G P Bodey, M Valdivieso.   

Abstract

Fifty-one previously untreated patients with advanced, measurable colorectal cancer were randomized to receive single doses of PALA and 5-FU either weekly (24 patients) or daily for 5 days every 4 weeks (27 patients). In both schedules the daily dose of PALA was administered iv over 1 hour, while the dose of 5-FU was administered iv over 30 minutes, starting 3 hours after completion of the PALA dose. Doses of both drugs were changed simultaneously, based on toxic effects. Partial responses were seen in four of 24 evaluable patients receiving the weekly regimen and in three of 26 patients receiving the 5-day regimen. Skin rash, mucositis, and diarrhea were the dose-limiting toxic effects in both treatment regimens. These toxic effects were more common and severe at higher doses and on the weekly schedule. Myelosuppression was mild and moderate, the doses and schedules used in this study did not significantly increase the activity of 5-FU. Further evaluation of these doses and schedules for activity against colorectal cancer is not warranted.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7273010

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  5 in total

Review 1.  How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.

Authors:  P Ragnhammar; H Blomgren
Journal:  Med Oncol       Date:  1995-09       Impact factor: 3.064

2.  A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.

Authors:  Robert P Whitehead; Jacqueline K Benedetti; James L Abbruzzese; Bach Ardalan; Stephen Williamson; Ellen R Gaynor; Stanley P Balcerzak; John S Macdonald
Journal:  Invest New Drugs       Date:  2004-11       Impact factor: 3.850

3.  A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU.

Authors:  G R Weiss; T J Ervin; M W Meshad; D Schade; A R Branfman; R J Bruni; M Chadwick; D W Kufe
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  Phase-I trial of combination therapy with continuous-infusion MMPR and continuous-infusion 5-FU.

Authors:  W P Peters; G Weiss; D W Kufe
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  5-fluorouracil metabolism monitored in vivo by 19F NMR.

Authors:  A N Stevens; P G Morris; R A Iles; P W Sheldon; J R Griffiths
Journal:  Br J Cancer       Date:  1984-07       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.